Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10376 Monotherapy in Patients With Advanced Non-small-Cell Lung Cancer

NCT05435274 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05435274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10376 Monotherapy in Patients With Advanced Non-small-Cell Lung Cancer
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2021
Completion date
October 7, 2025
Enrollment
380 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small-cell lung cancer